Drug Topics
MARCH 24, 2024
In a conversation at this year’s American Pharmacists Association Annual Meeting & Exposition, Sa’ed Al-Olimat outlined the potential of psychedelic therapeutics in treating mental health disorders.
Fierce Healthcare
MARCH 24, 2024
A new analysis pours cold water on the effectiveness of widely used digital diabetes management solutions, stirring up discussion about how best to evaluate the growing market of digital health too | The Peterson Health Technology Institute's analysis assessed whether digital diabetes solutions improve users' health outcomes over "usual care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MARCH 24, 2024
At this year’s American Pharmacists Association Annual Meeting & Exposition, Mark Garofoli urged pharmacists to develop strong documentation practices and go beyond baseline federal regulations to care for patients with red flags.
STAT
MARCH 24, 2024
There was a time when the last thing a celebrity would do would be to go public with details of a major illness. After all, it’s hard enough dealing with a grave diagnosis and often complicated treatments than to also announce them to the world. And health information has always been treated as confidential, shared between patients and their doctors.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
MARCH 24, 2024
An FDA executive discusses the Surgeon General’s recommendations for promoting mental health and wellbeing for employees in the workplace.
The FDA Law Blog
MARCH 24, 2024
By Faraz Siddiqui — As drug manufacturers battle the Health Resources and Services Administration (“HRSA”) in federal courts over the role of 340B contract pharmacies, an Eighth Circuit decision to uphold a 2021 Arkansas law may render those cases inconsequential in that state. The 340B contract pharmacy dispute involves several manufacturers who are refusing to provide 340B discounts to covered entities if they requested 340B drugs to be delivered to, and dispensed from, a network of contract p
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
BioPharm
MARCH 24, 2024
Webinar Date/Time: Thu, Thu, Apr 18, 2024 11:00 AM EDT
Pharmacy Times
MARCH 24, 2024
Food pharmacies, in particular, can be a great opportunity for pharmacists to collaborate with other providers, improve access to nutritious foods, and find unique opportunities to counsel patients.
BioPharm
MARCH 24, 2024
Webinar Date/Time: Thu, Apr 25, 2024 11:00 AM EDT
Pharmacy Times
MARCH 24, 2024
These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Med Ed 101
MARCH 24, 2024
An 89-year-old female has a history of hypertension, atrial fibrillation, stroke, GERD, osteoporosis, and osteoarthritis. Her current medication list includes the following: With a history of atrial fibrillation, stroke, and hypertension, this patient should be on anticoagulation. I do have concerns with rivaroxaban. The Beers criteria don’t prefer rivaroxaban unless there are concerns with patient […] The post Med List Review – Cardiovascular No-No’s appeared first on Me
Pharmacy Times
MARCH 24, 2024
A pharmacist discusses the impact of comprehensive weight management with a shared decision making approach.
BioPharm
MARCH 24, 2024
Partnering with a CDMO with collective insights and capabilities to support the development and manufacture of an innovative biotherapeutic program is an essential first step to providing better care to patients.
pharmaphorum
MARCH 24, 2024
Eisai and Biogen are facing a delay in the review of their Alzheimer's therapy Leqembi in the EU, for "procedural" reasons
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert insights. Personalized for you.
424 
Let's personalize your content